Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 9/20 | 0.71 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.71 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.71 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.70 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.70 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.70 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.70 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.70 |
| ▸ | RNASEL | Q05823 | 4/20 | 0.66 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL625113 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL20901220 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL14853693 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL19442379 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL14948858 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL14928757 | 0.99 | P2RY1 (0.72) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL18950213 | 0.93 | P2RY1 (0.63) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL263421 | 0.93 | CA5A (0.67) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL15071495 | 0.93 | CA5A (0.67) | P2RY1ENPP1P2RY12P2RX3P2RY11 | |
| SCHEMBL17010791 | 0.93 | CA5A (0.67) | P2RY1ENPP1P2RY12P2RX3P2RY11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-8304529-B2 | Dinucleotide MRNA cap analogs | Life Technologies Corporation (US) | 2012-11-06 | — | — | US | disclosed |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | LIFE TECHNOLOGIES CORPORATION, A DELAWARE CORPORATION (US) | 2010-10-14 | — | — | US | disclosed |
| EP-2049665-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | Applera Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008016473-A2 | DINUCLEOTIDE MRNA CAP ANALOGS | APPLERA CORPORATION (US) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | RNGTT, RNMT, NSUN2 | P2RY1 4232/4885ENPP1 1094/4885P2RY12 4303/4885 |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | RNGTT, RNMT, NSUN2 | P2RY1 4232/4885ENPP1 1094/4885P2RY12 4303/4885 |
| US-20100261231-A1 | Dinucleotide MRNA CAP Analogs | RNGTT, RNMT, NSUN2 | P2RY1 2373/4885ENPP1 724/4885P2RY12 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.